Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
120.4 USD -0.07% Intraday chart for Jazz Pharmaceuticals plc -2.97% -2.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating MT
Transcript : Jazz Pharmaceuticals plc - Special Call
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating MT
Transcript : Jazz Pharmaceuticals plc Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 02:00 PM
Transcript : Jazz Pharmaceuticals plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating MT
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016. CI
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours MT
Transcript : Jazz Pharmaceuticals plc, Q4 2023 Earnings Call, Feb 28, 2024
(JAZZ) JAZZ PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $18.15 - $19.35 MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue $4B-$4.2B MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q4 EPS $5.02, vs. Street Est of $5.18 MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q4 Revenue $1.01B, vs. Street Est of $1.01B MT
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024 CI
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Jazz Pharmaceuticals Announces Board Changes CI
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
Jazz Pharmaceuticals Names Philip Johnson as Chief Financial Officer MT
Chart Jazz Pharmaceuticals plc
More charts
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
120.4 USD
Average target price
188.8 USD
Spread / Average Target
+56.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Jazz Pharmaceuticals plc - Nasdaq
  4. News Jazz Pharmaceuticals plc
  5. Jazz Pharmaceuticals : Pharma Prices $1.5 Billion Senior Secured Notes Offering